<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article203</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/VADT" style="display:block; margin-bottom:10px;">VADT Original</a></li>
<h2><strong>VADT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Intensive Glucose Control in Type 2 Diabetes". The New England Journal of Medicine. 2009. 360:129-139. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does intensive glucose control reduce the rate of major cardiovascular events among patients with long-standing type 2 diabetes?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Intensive glucose control in patients with poorly controlled type 2 diabetes did not significantly reduce the rate of major cardiovascular events, death, or microvascular complications, except for a reduction in the progression of albuminuria.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last knowledge update for this summary, no specific guidelines have been generated based on this trial. However, guidelines generally suggest individualized glucose targets for patients with type 2 diabetes, taking into account the risk of hypoglycemia, patient preference, and disease duration.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, open-label, randomized, controlled trial<br/>
- N=1791 military veterans with type 2 diabetes and suboptimal response to therapy<br/>
- Intensive therapy (n=891); Standard therapy (n=900)<br/>
- Setting: 20 VA medical centers in the U.S.<br/>
- Enrollment: 2000-2003<br/>
- Follow-up: median 5.6 years<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Time to the first major cardiovascular event<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion criteria: Military veterans with type 2 diabetes and suboptimal response to therapy, glycated hemoglobin level &gt;7.5%<br/>
- Exclusion criteria: Recent cardiovascular event, advanced heart failure, limited life expectancy, BMI &gt;40, creatinine &gt;1.6 mg/dL, and alanine aminotransferase &gt;3× upper limit of normal<br/>
- Baseline characteristics: Mean age 60.4 years, 11.5 years since diabetes diagnosis, 40% had a cardiovascular event, 72% had hypertension<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Intensive therapy group: Goal glycated hemoglobin level reduction of 1.5% compared to the standard-therapy group<br/>
- Standard therapy group: Less aggressive glycemic targets<br/>
- Similar treatment for other cardiovascular risk factors<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: No significant difference in the time to the first occurrence of a major cardiovascular event between groups (HR 0.88; 95% CI 0.74 to 1.05; P=0.14)<br/>
- Secondary Outcomes: No significant difference in any of the individual components of the primary outcome or in all-cause death (HR 1.07; 95% CI 0.81 to 1.42; P=0.62)<br/>
- Adverse Events: Higher rate of hypoglycemia in the intensive-therapy group (24.1%) compared to standard-therapy group (17.6%, P=0.05)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Primarily male veteran population may limit generalizability to other groups<br/>
- Lack of double-blind design may have introduced bias<br/>
- Potential for newer agents to have different effects not considered in the trial protocol<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Veterans Affairs Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development, pharmaceutical and other supplies and financial assistance from GlaxoSmithKline, Novo Nordisk, Roche Diagnostics, Sanofi-Aventis, Amylin, and Kos Pharmaceuticals.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
